Acasti Pharma Inc. (ACST) 10-Q Quarterly Report February 2021

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Dec. 31, 2020	Feb. 09, 2021
Document Information [Line Items]
Entity Registrant Name	Acasti Pharma Inc.
Entity Central Index Key	0001444192
Trading Symbol	acst
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		179,495,705
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Shares, no par value per share

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1444192/000117184321000849/f10q_020921p.htm

View differences made from one quarter to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Mgmt Change

Other

Filter Subcategory:

All

Expense

Income

Cash Flow

Geography

Product

Other

Inside Acasti Pharma Inc.'s 10-Q Quarterly Report:

Financial - Expense Highlight
Stock-based compensation expense decreased to a gain of $30 for the three-month period ended December 31, 2020, as compared to a loss of $611 for the three-month period ended December 31, 2019.

Financial - Shares Highlight
Issued and outstanding fully paid shares, stock options, restricted shares units and warrants, were as follows for the periods ended: 31 As at December 31, 2020, cash and cash equivalents totaled $26,546, a net increase of $6,779 compared to cash and cash equivalents totaling $19,767 at December 31, 2019.
Financial - Expense Highlight
Under the fair value method, compensation cost is measured at fair value at date of grant and is expensed over the award's vesting period with a corresponding increase in additional paid-in capital.
Financial - Expense Highlight
The depreciation expense decreased by $110 for the three-month period ended December 31, 2020, as compared to $110 for the three-month period ended December 31, 2019.
Financial - Expense Highlight
The depreciation expense decreased by $129 for the nine-month period ended December 31, 2020, as compared to $1,449 for the nine-month period ended December 31, 2019.
Financial - Income
The decreased net loss resulted...Read more
Other - Other
Cash equivalents and marketable securities...Read more
Financial - Expense
General and administrative expenses totaled...Read more
Financial - Expense
In June 2016, the Financial...Read more
Financial - Expense
General and administrative expenses increased...Read more
Financial - Expense
The decrease in expense of...Read more
Financial - Expense
The decrease in expense of...Read more
Other - Other
The increase in cash used...Read more
Financial - Cash Flow
In assessing the magnitude of...Read more
Other - Other
Accordingly, an impairment loss of...Read more
Financial - Expense
In addition, a decrease in...Read more
Financial - Expense
In addition, a decrease in...Read more
Financial - Expense
The allowance for credit losses...Read more
Financial - Expense
General and administrative expenses totaled...Read more
Other - Other
We also announce the departure...Read more
Revenue - Geography
We have credit risk relating...Read more
Revenue - Product
Under the terms of the...Read more
Financial - Expense
For assets held at amortized...Read more
Financial - Cash Flow
If the carrying amount is...Read more
Other - Other
The Registration Statement was declared...Read more
Other - Other
However, in light of our...Read more
Financial - Expense
The reduction in net loss...Read more
Revenue - Product
On February 14, 2019, the...Read more
Other - Other
This ASU is effective for...Read more
Financial - Expense
Total costs incurred to register...Read more
Revenue - Geography
A total of 10,188,100 warrants...Read more
Other - Other
Any impairment loss to be...Read more
Other - Other
ASU 2016-13 is effective for...Read more
Other - Other
The December 2017 warrants are...Read more
Other - Other
The warrants forming part of...Read more
Financial - Expense
Stock-based compensation expense increased to...Read more
Mgmt Change - Other
As a result of disappointing...Read more
Financial - Cash Flow
The Corporation has incurred operating...Read more
Financial - Expense
In August 2018, the FASB...Read more
Other - Other
Changes to the expected volatility...Read more
Other - Other
Furthermore, a portion of our...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ACST
CIK: 1444192
Form Type: 10-Q Quarterly Report
Accession Number: 0001171843-21-000849
Submitted to the SEC: Tue Feb 09 2021 7:00:32 AM EST
Accepted by the SEC: Tue Feb 09 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations